OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
27 April 2023 - 6:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease,
reported today that its German subsidiary Curetis GmbH has met the
remaining key milestones under the initial research and development
(“R&D”) collaboration agreement with FIND. Following the
delivery of a comprehensive milestone report at the end of first
quarter of 2023, FIND confirmed that all requirements have been met
successfully. Under the recently announced expansion of the
collaboration, the originally planned Next Generation Sequencing
(“NGS”) strain analysis will be complemented with isolates from
other sub-Saharan African countries. Completion of the deliverables
triggered a milestone payment of approximately $0.3 million.
The R&D collaboration to date has
successfully addressed the development and initial wet-lab testing
of a sample-in to result-out Unyvero A30 panel with 33 targets,
including fully integrated sample preparation. Multiple Unyvero A30
instrument adaptations were made to optimize for use in the
challenging environments of low- and middle- income countries
(LMICs). Instrument prototypes have been designed, built and tested
for operation in high-dust, extended temperature range and
power-out scenarios.
Andreas Boos, Chief Technology Officer at
Curetis GmbH commented: “We are excited to have successfully
delivered the final milestones from the first phase of our
collaboration agreement and look forward to working on the next set
of deliverables under the expanded scope of our R&D partnership
with FIND.”
Johannes Bacher, Chief Operating Officer of
OpGen added: “We believe the successful first phase of our
development collaboration puts us in an ideal position towards
development of a robust solution optimized for use in LMICs, a goal
we would like to pursue during a potential next phase of this
collaboration under a new agreement with FIND.”
Dr. Cecilia Ferreyra, Director, FIND AMR
Programme remarked that, “We have evaluated the final milestone
data from Curetis on the Unyvero A30 and have confirmed that the
adapted prototype test meets the quality and accuracy requirements
for use in low- and middle-income countries. We look forward to
potential continued collaboration to expand testing for blood
stream infections in LMIC hospitals so that people can be linked to
the care they need as soon as possible.”
About OpGen,
Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH,
we are developing and commercializing molecular microbiology
solutions helping to guide clinicians with more rapid and
actionable information about life threatening infections to improve
patient outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s current
product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the
ARES Technology Platform including ARESdb, NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction including ARESiss, ARESid, ARESasp, and AREScloud, as
well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test
kit.
For more information, please
visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
milestones under OpGen’s collaboration with FIND. These statements
and other statements regarding OpGen’s future plans and goals
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and are intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
the success of our commercialization efforts, our ability to
successfully, timely and cost-effectively develop, seek and obtain
regulatory clearance for and commercialize our product and services
offerings, the rate of adoption of our products and services by
hospitals and other healthcare providers, the fact that we may not
effectively use proceeds from recent financings, , our ability to
satisfy debt obligations under our loan with the European
Investment Bank, the effect of the military action in Russia and
Ukraine on our distributors, collaborators and service providers,
our liquidity and working capital requirements, the effect on our
business of existing and new regulatory requirements, and other
economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Investor & Press Contact:Alyssa
FactorEdison Groupafactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024